Featured Article Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
暂无分享,去创建一个
E. Siemers | M. Pontecorvo | R. Dean | M. Case | G. Sethuraman | R. Demattos | S. Dowsett | H. Liu-Seifert | K. Sundell | Christopher Carlson | R. DeMattos
[1] Nick C Fox,et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[2] John Hardy,et al. Antiamyloid therapy for Alzheimer's disease--are we on the right road? , 2014, The New England journal of medicine.
[3] E. Siemers,et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[4] E. Siemers,et al. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease , 2012, Alzheimer's & Dementia.
[5] F. Barkhof,et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. , 2012, Archives of neurology.
[6] Bruno Vellas,et al. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer’s disease trials , 2011, Alzheimer's & Dementia.
[7] E. Siemers,et al. Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid &bgr; After a Single Administration of an Amyloid &bgr; Monoclonal Antibody in Subjects With Alzheimer Disease , 2010, Clinical neuropharmacology.
[8] Nick C Fox,et al. The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.
[9] Nick C Fox,et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease , 2009, Neurology.
[10] E. Siemers,et al. Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease , 2009, Expert opinion on pharmacotherapy.
[11] P. Calabresi,et al. Pattern of Tau forms in CSF is altered in progressive supranuclear palsy , 2009, Neurobiology of Aging.
[12] J. Trojanowski,et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology , 2008, Neurology.
[13] Christopher Clark,et al. Disease-modifying therapies for Alzheimer disease , 2007, Neurology.
[14] Jennifer Farmer,et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease , 2005, Annals of neurology.
[15] Nick C Fox,et al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.
[16] D. Holtzman,et al. Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease , 2002, Science.
[17] C. MacKnight,et al. Interrater Reliability of the Clinical Dementia Rating in a Multicenter Trial , 2000, Journal of the American Geriatrics Society.
[18] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[19] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[20] G. Schellenberg,et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. , 2014, JAMA.
[21] H. Vanderstichele,et al. Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab. , 2013, Journal of Alzheimer's disease : JAD.
[22] M. Sano,et al. An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.
[23] R. Petersen,et al. Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs: Additions to the Alzheimer's Disease Assessment Scale That Broaden Its Scope , 1997, Alzheimer disease and associated disorders.